Summary
Definition
History and exam
Key diagnostic factors
- pelvic mass
- ascites
- pleural effusion
Other diagnostic factors
- gastrointestinal symptoms
- urinary urgency or frequency
- symptom duration >3 months
- abdominal distention
- pelvic/abdominal pain or pressure
Risk factors
- genetic mutations associated with hereditary ovarian cancer
- increasing age
- family history of ovarian cancer, breast cancer, colorectal cancer, and/or endometrial cancer
- never used combined oral contraceptives
- nulliparity
- obesity
- hormone therapy
- endometriosis
Diagnostic tests
1st tests to order
- pelvic ultrasound
- CA-125
- histopathology
Tests to consider
- genetic testing
- PET, PET-CT, or PET/MRI
- MRI
- CT scan
- biomarker tests
Treatment algorithm
surgical candidate, intraoperative histology confirmed disease
poor surgical candidate, biopsy confirmed disease
platinum-sensitive recurrent disease
platinum-resistant recurrent or refractory disease
Contributors
Authors
Sareena Singh, MD
Gynecologic Oncologist
Aultman Medical Group
Northeast Ohio Medical University
Canton
OH
Declarações
SS declares that she has no competing interests.
Agradecimentos
Dr Sareena Singh would like to gratefully acknowledge Dr Justin C. Chura and Dr Allison E. Axtell, previous contributors to this topic.
Declarações
JCC and AEA declare that they have no competing interests.
Revisores
Michael P. Hopkins, MD, MEd
Chairman
Obstetrics and Gynecology
Northeast Ohio Universities of Medicine (NEOMED)
Rootstown
OH
Declarações
MPH declares that he has no competing interests.
Ritu Salani, MD
Gynecologic Oncology Fellow
Johns Hopkins Medical Institutions
Baltimore
MD
Declarações
RS declares that she has no competing interests.
Susan A. Davidson, MD
Associate Professor
Chief, Gynecologic Oncology
Department of Obstetrics & Gynecology (UCD)
University of Colorado Cancer Center
Aurora
CO
Declarações
SAD declares that she has no competing interests.
Khadra Galaal, MBChB, MPH, MRCOG
Consultant Gynaecological Oncologist
Northern Gynaecological Oncology Centre
Queen Elizabeth Hospital
Gateshead
UK
Declarações
KG is co-author of a systematic review of follow-up strategies after primary treatment in ovarian cancer. This is not referenced in this topic.
Jill Tseng, MD
Assistant Clinical Professor of Gynecologic Oncology
University of California, Irvine
Orange
CA
Declarações
JT declares that she has no competing interests.
Créditos aos pareceristas
Os tópicos do BMJ Best Practice são constantemente atualizados, seguindo os desenvolvimentos das evidências e das diretrizes. Os pareceristas aqui listados revisaram o conteúdo pelo menos uma vez durante a história do tópico.
Declarações
As afiliações e declarações dos pareceristas referem--se ao momento da revisão.
Referências
Principais artigos
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: ovarian cancer including fallopian tube cancer and primary peritoneal cancer [internet publication].Texto completo
González-Martín A, Harter P, Leary A, et al. Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2023 Oct;34(10):833-48.Texto completo Resumo
Gaillard S, Lacchetti C, Armstrong DK, et al. Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update. J Clin Oncol. 2025 Mar;43(7):868-91.Texto completo Resumo
Berek JS, Renz M, Kehoe S, et al. Cancer of the ovary, fallopian tube, and peritoneum: 2021 update. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(suppl 1):61-85.Texto completo Resumo
Tew WP, Lacchetti C, Kohn EC, et al. Poly(ADP-Ribose) polymerase inhibitors in the management of ovarian cancer: ASCO guideline rapid recommendation update. J Clin Oncol. 2022 Nov 20;40(33):3878-81.Texto completo Resumo
Artigos de referência
Uma lista completa das fontes referenciadas neste tópico está disponível para os usuários com acesso total ao BMJ Best Practice.

Diagnósticos diferenciais
- Irritable bowel syndrome (IBS)
- Metastases to the ovary
- Endometriosis
Mais Diagnósticos diferenciaisDiretrizes
- Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian cancer: ASCO guideline update
- Ovarian epithelial, fallopian tube, and primary peritoneal cancer treatment
Mais DiretrizesFolhetos informativos para os pacientes
Ovarian cancer: what is it?
Ovarian cancer: what are the treatment options?
Mais Folhetos informativos para os pacientesConectar-se ou assinar para acessar todo o BMJ Best Practice
O uso deste conteúdo está sujeito ao nosso aviso legal